A carregar...
Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway
Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibody-secreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains i...
Na minha lista:
| Publicado no: | Oncol Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cognizant Communication Corporation
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7848415/ https://ncbi.nlm.nih.gov/pubmed/30837032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15443011011637 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|